BUZZ-據報導，Summit Therapeutics 公司與阿斯利康公司就許可協議進行了談判，公司業績因此上漲

路透中文

07/03

BUZZ-據報導，<a href="https://laohu8.com/S/SMMT">Summit</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> 公司與<a href="https://laohu8.com/S/AZN">阿斯利康</a>公司就許可協議進行了談判，公司業績因此上漲

7月3日 - ** 藥物開發商Summit Therapeutics SMMT.O股價上漲3%，至23.30美元

** 彭博新聞社（(link)）援引知情人士的話報導說，阿斯利康AZN.L正在與Summit洽談合作事宜，將以高達150億美元的價格獲得一種肺癌藥物ivonescimab的許可。

** 報導稱，Summit 還在與其他大型製藥公司商談潛在合作事宜

** Summit 沒有立即回應路透的置評請求，而阿斯利康發言人拒絕置評

** 包括本交易日在內，該股今年累計上漲 25.6

(爲便利非英文母語者，路透將其報導自動化翻譯爲數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是爲了便利讀者而提供自動化翻譯。對於因爲使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2548383057"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548383057\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548383057?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-03 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548383057","market":"us","top_or_hot":-1,"title":"BUZZ-據報導，Summit Therapeutics 公司與阿斯利康公司就許可協議進行了談判，公司業績因此上漲","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-據報導，<a href=\"https://laohu8.com/S/SMMT\">Summit</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 公司與<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司就許可協議進行了談判，公司業績因此上漲</title></head><body><p>\n<span>7月3日</span><span> - </span> ** 藥物開發商Summit Therapeutics <span>SMMT.O</span>股價上漲3%，至23.30美元</p><p> ** 彭博新聞社（(<span>link</span>)）援引知情人士的話報導說，阿斯利康<span>AZN.L</span>正在與Summit洽談合作事宜，將以高達150億美元的價格獲得一種肺癌藥物ivonescimab的許可。</p><p> ** 報導稱，Summit 還在與其他大型製藥公司商談潛在合作事宜</p><p> ** Summit 沒有立即回應路透的置評請求，而阿斯利康發言人拒絕置評</p><p> ** 包括本交易日在內，該股今年累計上漲 25.6</p><p>(爲便利非英文母語者，路透將其報導自動化翻譯爲數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是爲了便利讀者而提供自動化翻譯。對於因爲使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-據報導，Summit Therapeutics 公司與阿斯利康公司就許可協議進行了談判，公司業績因此上漲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-據報導，Summit Therapeutics 公司與阿斯利康公司就許可協議進行了談判，公司業績因此上漲\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2025-07-03 23:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-據報導，<a href=\"https://laohu8.com/S/SMMT\">Summit</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 公司與<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司就許可協議進行了談判，公司業績因此上漲</title></head><body><p>\n<span>7月3日</span><span> - </span> ** 藥物開發商Summit Therapeutics <span>SMMT.O</span>股價上漲3%，至23.30美元</p><p> ** 彭博新聞社（(<span>link</span>)）援引知情人士的話報導說，阿斯利康<span>AZN.L</span>正在與Summit洽談合作事宜，將以高達150億美元的價格獲得一種肺癌藥物ivonescimab的許可。</p><p> ** 報導稱，Summit 還在與其他大型製藥公司商談潛在合作事宜</p><p> ** Summit 沒有立即回應路透的置評請求，而阿斯利康發言人拒絕置評</p><p> ** 包括本交易日在內，該股今年累計上漲 25.6</p><p>(爲便利非英文母語者，路透將其報導自動化翻譯爲數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是爲了便利讀者而提供自動化翻譯。對於因爲使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nL4T3T010M:1","article_id":"2548383057","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548383057","pubTimestamp":1751554847,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"7月3日 -  ** 藥物開發商Summit Therapeutics SMMT.O股價上漲3%，至23.30美元 ** 彭博新聞社援引知情人士的話報導説，阿斯利康AZN.L正在與Summit洽談合作事宜，將以高達150億美元的價格獲得一種肺癌藥物ivonescimab的許可。** 報導稱，Summit 還在與其他大型製藥公司商談潛在合作事宜 ** Summit 沒有立即回應路透的置評請求，而阿斯利康發言人拒絕置評 ** 包括本交易日在內，該股今年累計上漲 25.6(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1078025761.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USDHDG) ACC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU2279689827.SGD":"JPMorgan Investment Funds - Global Income Sustainable A (mth) SGD-H","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0889565080.SGD":"FTIF - Templeton European Opportunities A Acc SGD-H1","LU0882574055.USD":"富达全球健康医疗A ACC","AZN.UK":"阿斯利康制药","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0499090636.EUR":"AZ FUND 1 DIVIDEND PREMIUM \"A-AZ\" ACC","BK5011":"制药","LU0640478417.SGD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AGH\" (SGDHDG) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0784384876.USD":"Blackrock Global Multi-Asset Income A6 USD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0972486137.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AUH\" (USDHDG) ACC","LU0784385840.USD":"Blackrock Global Multi-Asset Income A2 USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1064927863.SGD":"JPMorgan Funds - Europe Dynamic A (acc) SGD-H","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU0964806797.USD":"UBS (LUX) EQUITY FUND - EUROPEAN OPPORTUNITY SUSTAINABLE (EUR) \"P\" (USHDG) ACC","03165":"华夏欧优股对冲","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","SMMT":"Summit Therapeutics PLC","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU0963555726.SGD":"Blackrock European Fund A2 SGD-H","LU0557290698.USD":"施罗德环球可持续增长基金","LU0757432116.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AE\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"translate_title":"BUZZ-Summit Therapeutics results rose as company reportedly negotiated a licensing agreement with AstraZeneca","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"AZN.UK":0.9,"SMMT":0.9},"content_text":"BUZZ-據報導，Summit Therapeutics 公司與阿斯利康公司就許可協議進行了談判，公司業績因此上漲\n7月3日 -  ** 藥物開發商Summit Therapeutics SMMT.O股價上漲3%，至23.30美元 ** 彭博新聞社（(link)）援引知情人士的話報導説，阿斯利康AZN.L正在與Summit洽談合作事宜，將以高達150億美元的價格獲得一種肺癌藥物ivonescimab的許可。 ** 報導稱，Summit 還在與其他大型製藥公司商談潛在合作事宜 ** Summit 沒有立即回應路透的置評請求，而阿斯利康發言人拒絕置評 ** 包括本交易日在內，該股今年累計上漲 25.6(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}